IMVT
Bearish signalScored 2026-10-25 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Immunovant, Inc.
- Nom
- Immunovant, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $5.8B
- Employés
- 315
- PDG
- Eric Venker
- Site web
- https://immunovant.com
- Marché
- ACRSANABANNXCABACGEMIMUX
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 5 006 titres (~184 494,66 $ US)
- Insiders
- Venker EricPande Atul
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$663,585
Avg sell (VWAP, 90d window) $35.55 vs last close $28.17 (-20.8%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$64,905 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-02
- Liquidity
- Liquid $39,839,841/day · 20d vol
- Last synced
-
2026-10-26 21:10:34
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-21 | Stout Jay S | Sell · S | 2,595 | $28.94 | $75,099 | Form 4 |
| 2026-10-07 | Gloria Melanie | Sell · S | 2,241 | $32.06 | $71,846 | Form 4 |
| 2026-10-07 | Stout Jay S | Sell · S | 1,596 | $32.06 | $51,168 | Form 4 |
| 2026-10-07 | Van Tuyl Christopher | Sell · S | 1,327 | $32.06 | $42,544 | Form 4 |
| 2026-10-02 | Venker Eric | Sell · S | 3,506 | $34.11 | $119,590 | Form 4 |
| 2026-09-23 | Van Tuyl Christopher | Sell · S | 2,846 | $36.36 | $103,481 | Form 4 |
| 2026-08-28 | Pande Atul | Sell · S · 10b5-1 | 1,500 | $43.27 | $64,905 | Form 4 |
| 2026-08-20 | Gloria Melanie | Sell · S | 3,056 | $44.16 | $134,953 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-25 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 9.09 · operating margin 0.0%
Suggested stop 25.80, nearest stored support minus 0.5 ATR(8.4% under the last close). Reward/risk to the next stored resistance is 0.46. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-21 Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the second fiscal quarter ended September 30, 2026 on Monday, November 9, 2026 before the market opens. Roivant Sciences Ltd. (Nasdaq: ROIV), Immunovant''s majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that same day, which will include a business update for Immunovant.
- 2026-10-12 Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC,
- 2026-10-12 Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
- 2026-10-11 IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law [url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
- 2026-10-11 IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $IMVT--IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law.
- 2026-09-25 Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT) Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)PR NewswireNEW YORK, Sept. 25, 2026Immunovant stock
- 2026-09-25 Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT) Immunovant stock fell roughly 6% to a more-than-three-month low on September 23, 2026 after the IMVT-1402 cutaneous lupus study missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of IMVT investors who lost money.
- 2026-09-24 IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down Immunovant''s IMVT-1402 misses its primary CLE goal, prompting the company to halt the program despite positive trends and a favorable safety profile.
- 2026-09-23 Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus Immunovant''s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12 Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant''s internal bar to continue development of IMVT-1402 in CLE IMVT-1402 demonstrated a favorable safety and tolerability profile, consistent with prior studies All other clinical development timelines remain on track BASEL, Switzerland and LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced topline results from Period 1 of Immunovant''s proof-of-concept trial evaluating IMVT-1402 (imeroprubart) for the treatment of cutaneous lupus erythematosus (CLE).
- 2026-09-23 Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus Immunovant''s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12 Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant''s internal bar to continue development of IMVT-1402 in CLE IMVT-1402 demonstrated a favorable safety and tolerability profile, consistent with prior studies All other clinical development timelines remain on track DURHAM, N.C., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 (imeroprubart) for the treatment of cutaneous lupus erythematosus (CLE).
Market snapshot
Financial ratios
| Metric | Trend | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 9.086 | 11.162 | 13.697 | 9.339 | 11.521 | |
| Quick Ratio | 9.086 | 11.162 | 13.697 | 9.339 | 11.521 | |
| Solvency Ratio | -4.813 | -6.012 | -5.293 | -4.863 | -3.424 | |
| Cash Ratio | 8.639 | 10.381 | 13.071 | 8.696 | 11.092 | |
| Price To Earnings Ratio | -8.968 | -6.260 | -16.814 | -9.070 | -3.853 | |
| Price To Earnings Growth Ratio | -6.120 | -0.138 | -1.691 | -0.463 | -0.224 | |
| Forward Price To Earnings Growth Ratio | -6.120 | -0.138 | -1.691 | -0.463 | -0.224 | |
| Price To Earnings Diluted Ratio | -8.968 | -6.260 | -16.814 | -9.070 | -3.853 | |
| Price To Earnings Diluted Growth Ratio | -6.120 | -0.138 | -1.691 | -0.463 | -0.224 | |
| Price To Book Ratio | 5.315 | 3.662 | 7.066 | 5.266 | 1.286 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -11.125 | -6.878 | -20.343 | -10.133 | -5.682 | |
| Price To Operating Cash Flow Ratio | -11.125 | -6.892 | -20.377 | -10.143 | -5.695 | |
| Debt To Assets Ratio | 0.000 | 0.000 | 0.000 | 0.003 | 0.005 | |
| Debt To Equity Ratio | 0.000 | 0.000 | 0.000 | 0.003 | 0.005 | |
| Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.003 | 0.005 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.123 | 1.097 | 1.079 | 1.120 | 1.097 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -3.901 | -5.465 | -4.407 | -4.347 | -2.383 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.002 | 1.002 | 1.001 | 1.002 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | -15.886 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -16.686 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -5,657.083 | -3,835.449 | -1,552.370 | -154.257 | -44.887 | |
| Capital Expenditure Coverage Ratio | -50,913.750 | -495.223 | -595.075 | -955.294 | -417.764 | |
| Dividend Paid And Capex Coverage Ratio | -50,913.750 | -495.223 | -595.075 | -955.294 | -417.764 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -7.187 | -4.548 | -14.428 | -7.735 | -0.720 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 9.086 | ▼-2.075 | ▼-1.875 |
| Quick Ratio | 9.086 | ▼-2.075 | ▼-1.875 |
| Solvency Ratio | -4.812 | ▲1.199 | ▲0.068 |
| Cash Ratio | 8.639 | ▼-1.742 | ▼-1.737 |
| Price To Earnings Ratio | -8.967 | ▼-2.707 | ▲0.025 |
| Price To Earnings Growth Ratio | -6.120 | ▼-5.982 | ▼-4.393 |
| Forward Price To Earnings Growth Ratio | -6.120 | ▼-5.982 | ▼-4.393 |
| Price To Earnings Diluted Ratio | -8.967 | ▼-2.707 | ▲0.025 |
| Price To Earnings Diluted Growth Ratio | -6.120 | ▼-5.982 | ▼-4.393 |
| Price To Book Ratio | 5.315 | ▲1.653 | ▲0.796 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -11.125 | ▼-4.247 | ▼-0.293 |
| Price To Operating Cash Flow Ratio | -11.125 | ▼-4.233 | ▼-0.279 |
| Debt To Assets Ratio | 0.000 | ▼-0.000 | ▼-0.002 |
| Debt To Equity Ratio | 0.000 | ▼-0.000 | ▼-0.002 |
| Debt To Capital Ratio | 0.000 | ▼-0.000 | ▼-0.002 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.123 | ▲0.026 | ▲0.020 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -3.901 | ▲1.565 | ▲0.200 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.002 | ▼-0.001 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲3.177 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲3.337 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -5657.083 | ▼-1821.634 | ▼-3408.274 |
| Capital Expenditure Coverage Ratio | -50913.750 | ▼-50418.527 | ▼-40238.329 |
| Dividend Paid And Capex Coverage Ratio | -50913.750 | ▼-50418.527 | ▼-40238.329 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -7.187 | ▼-2.639 | ▼-0.263 |
Key metrics
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Market cap | $4.53B | $2.59B | $4.37B | $1.91B | $604.3M | |
| Enterprise value | $3.63B | $1.88B | $3.73B | $1.53B | $112.9M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -8.91x | -4.99x | -17.41x | -8.15x | -1.06x | |
| EV / Free cash flow | -8.91x | -4.98x | -17.38x | -8.14x | -1.06x | |
| EV / EBITDA | -7.19x | -4.55x | -14.43x | -7.74x | -0.72x | |
| Net debt / EBITDA | 1.79x | 1.73x | 2.46x | 1.89x | 3.14x | |
| Current ratio | 9.09x | 11.16x | 13.70x | 9.34x | 11.52x | |
| Income quality | 0.81x | 0.91x | 0.83x | 0.89x | 0.68x | |
| Graham net-net | $4 | $4 | $4 | $3 | $4 | |
| Tax burden | 100.0% | 100.2% | 100.2% | 100.0% | 99.9% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 106.3% | 100.0% | |
| Working capital | $844.4M | $698.9M | $617.2M | $361.0M | $468.4M | |
| Invested capital | $844.9M | $699.8M | $617.8M | $362.5M | $471.0M | |
| Return on assets | -52.8% | -53.3% | -38.9% | -52.0% | -30.4% | |
| Operating ROA | -61.5% | -60.7% | -50.4% | -45.2% | -33.6% | |
| Return on tangible assets | -52.8% | -53.3% | -38.9% | -52.0% | -30.4% | |
| Return on equity | -59.3% | -58.5% | -42.0% | -58.2% | -33.4% | |
| Return on invested capital | -62.5% | -61.9% | -43.7% | -57.3% | -33.0% | |
| Return on capital employed | -62.5% | -61.9% | -43.7% | -57.4% | -33.1% | |
| Earnings yield | -11.2% | -16.0% | -5.9% | -11.1% | -25.9% | |
| Free cash flow yield | -9.0% | -14.5% | -4.9% | -9.9% | -17.6% | |
| Capex / Op. cash flow | -0.0% | -0.2% | -0.2% | -0.1% | -0.2% | |
| Capex / Depreciation | 2.0% | 201.3% | 155.8% | 102.1% | 201.6% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 6730d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -6730d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years